Respondents’ views on provision of the progestogen-only pill and combined oral contraception in the pharmacy setting
| Strongly support (n (%)) | Support (n (%)) | Neutral (n (%)) | Oppose (n (%)) | Strongly oppose (n (%)) | Total (n) | |
| Pharmacy provision of POP | ||||||
| PGD – initiation | 81 (46.8) | 54 (31.2) | 19 (11.0) | 17 (9.8) | 2 (1.2) | 173 |
| PGD – continuation | 114 (65.5) | 44 (25.3) | 10 (5.7) | 5 (2.9) | 1 (0.6) | 174 |
| Pharmacy medicine | 50 (28.9) | 52 (30.1) | 29 (16.8) | 33 (19.1) | 9 (5.2) | 173 |
| General sales list medicine | 16 (9.5) | 20 (11.8) | 26 (15.4) | 80 (47.3) | 27 (16.0) | 169 |
| Pharmacy provision of COC | ||||||
| PGD - initiation | 44 (25.7) | 40 (23.4) | 37 (21.6) | 41 (24.0) | 9 (5.3) | 171 |
| PGD - continuation | 78 (45.3) | 63 (36.6) | 15 (8.7) | 11 (6.4) | 5 (2.9) | 172 |
| Pharmacy medicine | 25 (14.5) | 43 (24.9) | 27 (15.6) | 48 (27.7) | 30 (17.3) | 173 |
| General sales list medicine | 8 (4.7) | 12 (7.0) | 17 (9.9) | 69 (40.4) | 65 (38.0) | 171 |
COC, combined oral contraception; PGD, patient group direction; POP, progestogen-only pill.